Stem Cell Therapeutics Appoints Dr. Robert Kirkman to Its Board of Directors
2013年12月17日 - 9:00PM
Marketwired
Stem Cell Therapeutics Appoints Dr. Robert Kirkman to Its Board of
Directors
Provides update on $33 million Offering
TORONTO, ONTARIO--(Marketwired - Dec 17, 2013) - Stem Cell
Therapeutics Corp. (TSX-VENTURE:SSS)(OTCQX:SCTPF), an
immuno-oncology company developing cancer stem cell-related
therapeutics, today announced that industry veteran Dr. Robert L.
Kirkman has been appointed to the Company's Board of Directors.
Dr. Kirkman has
broad executive experience from several public biotechnology
companies. He currently serves as the President and Chief Executive
Officer of Oncothyreon Inc., an oncology company with a
long-established interest in the immunotherapy field. He previously
held various executive positions at Xcyte Therapies, another
immunotherapy company, and Protein Design Labs. Dr. Kirkman began
his career as a clinician-scientist, holding various positions at
Brigham and Women's Hospital, Boston, including Chief, Division of
Transplantation. Dr. Kirkman holds an M.D. degree from Harvard
Medical School and a B.A. in economics from Yale University.
"We are delighted to
welcome Dr. Kirkman to the Board of Directors. His extensive
expertise as a life science industry executive and a clinician, as
well as his in-depth knowledge of the capital markets, adds
immeasurable value to our company," stated Mr. David Allan, Stem
Cell Therapeutics' Chairman.
In connection with
the completion of the $33 million offering announced on December
13, 2013, the Company issued 157,142,858 units at a price of $0.21
each. U.S.-based investors subscribed for approximately 97% of the
issue. The units consisted of either one common share and
three-quarters of a common share purchase warrant ("Common Share
Units") or one Series 1 Non-Voting First Preferred Share and
three-quarters of a common share purchase warrant ("Preferred Share
Unit"). Of the total Units issued, 79,247,693 units were Common
Share Units and 77,895,165 units were Preferred Shares Units. Each
whole warrant entitles the holder to purchase one common share at a
price of $0.28 at any time prior to expiry on December 13, 2018.
Each preferred shareholder has the right to convert all or any of
their preferred shares into an equal number of common shares, as
adjusted for stock splits, certain distributions and other
fundamental transactions. The articles of amendment creating the
new class of preferred shares have been filed on Sedar at
www.sedar.com. Following the offering, the Company has 121,752,380
common shares issued and outstanding (344,798,764 on a fully
diluted basis).
About Stem Cell
Therapeutics:
Stem Cell
Therapeutics Corp. (SCT) is an immuno-oncology company advancing
cancer stem cell discoveries into novel and innovative cancer
therapies. Building on over half a century of leading and
groundbreaking Canadian stem cell research, the company is
supported by established links to a group of prominent Toronto
academic research institutes and cancer treatment centers,
representing one of the world's most acclaimed cancer research
hubs. The Company has two premier preclinical programs, SIRPaFc and
a CD200 monoclonal antibody (mAb), which target two key
immunoregulatory pathways that tumor cells exploit to evade the
host immune system. SIRPaFc is an antibody-like fusion protein that
blocks the activity of CD47, a molecule that is upregulated on
cancer stem cells in AML and several other tumors. The CD200 mAb is
a fully human monoclonal antibody that blocks the activity of
CD200, an immunosuppressive molecule that is overexpressed by many
hematopoietic and solid tumors. SCT's clinical stage programs
include the recently in-licensed program focused on the structure
of tigecycline, which is currently being evaluated in a
multi-centre Phase I study in patients with acute myeloid leukemia
(AML), as well as TTI-1612, a non-cancer stem cell asset that
recently completed a 28-patient Phase I trial in interstitial
cystitis ("IC") patients. For more information, visit:
www.stemcellthera.com.
Caution Regarding
Forward-Looking Information:
This press release
may contain forward-looking statements, which reflect SCT's current
expectation regarding future events. These forward-looking
statements involve risks and uncertainties that may cause actual
results, events or developments to be materially different from any
future results, events or developments expressed or implied by such
forward-looking statements. Such factors include changing market
conditions; the successful and timely completion of pre-clinical
and clinical studies; the establishment of corporate alliances; the
impact of competitive products and pricing; new product development
risks; uncertainties related to the regulatory approval process or
the ability to obtain drug product in sufficient quantity or at
standards acceptable to health regulatory authorities to complete
clinical trials or to meet commercial demand; and other risks
detailed from time to time in SCT's ongoing quarterly and annual
reporting. Except as required by applicable securities laws, SCT
undertakes no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise.
Neither TSX Venture
Exchange nor its Regulation Services Provider (as that term is
defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.
Stem Cell Therapeutics Corp.James ParsonsChief Financial
Officer+1 416 595
0627jparsons@stemcellthera.comwww.stemcellthera.comInvestor
Contact:Jeff Ramson/Kirin SmithProActive Capital+1
646-863-6519jramson@proactivecapital.comksmith@proactivecapital.com
Sunvest Minerals Corp (TSXV:SSS)
過去 株価チャート
から 5 2024 まで 6 2024
Sunvest Minerals Corp (TSXV:SSS)
過去 株価チャート
から 6 2023 まで 6 2024